Genvoya

Product NDC

50090-2279

11-digit product format

500902279

Labeler code

50090

Product ID

50090-2279_4d9620da-767c-4e13-ac6e-2c3ec0ecdbcf

Type

HUMAN PRESCRIPTION DRUG

Nonproprietary name

elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide

Dosage form

TABLET

Route

ORAL

Labeler

A-S Medication Solutions

Application

NDA207561

Marketing category

NDA

Marketing start

2015-11-05

Marketing end

0000-00-00

Substance

ELVITEGRAVIR; COBICISTAT; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Active strength

150 mg/1; mg/1; mg/1; mg/1

Pharmacologic classes

HIV Integrase Inhibitors [MoA],Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC],Cytochrome P450 2C9 Inducers [MoA],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 3A Inhibitor [EPC],P-Glycoprotein Inhibitors [MoA],Cytochrome P450 2D6 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

NDC exclude flag

No

Listing certified through

2019-12-31

Current FDA listing

Historical FDA.report record